this route of transmission plays a significant role.
Nevertheless, there were several areas in Dr Aggarwal's letter that we wish to clarify. First, we believe that, in this epidemic, which continued over many incubation periods, there must have been either a continuing common source or person-toperson transmission. During the period of this investigation, there were several prevention and control measures implemented to ensure safe drinking water and hygienic practices. In addition to hepatitis E virus testing of water sources, testing for coliforms was conducted. Although we agree with Dr Aggarwal regarding the low sensitivity of hepatitis E virus detection techniques from water sources, the absence of hepatitis E virus RNA and significant coliforms from protected water sources argues against any fecal contamination that would contribute to an ongoing common source. Given that there was no evidence of any contamination of these sources while hand lavage yielded hepatitis E virus [2] , we believe that person-to-person transmission likely played a significant role.
Second, we believe that the assumption of secondary cases representing person-toperson transmission is conservative in that this route could also have contributed to transmission among primary cases. Unlike in Asia, where there may be a higher prevalence of immunity to hepatitis E virus, we believe that a significant proportion of the population was susceptible to hepatitis E virus prior to the widespread outbreak. In our population, this could have contributed to the secondary attack rate, which was much higher than those reported in most studies [3] , which were conducted in populations with higher preexisting immunity to hepatitis E virus and where person-to-person transmission was considered insignificant. If there had been a continually contaminated common water source, then we would have expected an even higher attack rate and a shorter outbreak. Regarding Dr Aggarwal's concern about the range of time periods between primary and secondary cases (ie, 8-20 weeks), we believe that infection could have been propagated by infected but asymptomatic family members.
Another issue regarding household transmission that was raised by Dr Aggarwal deserves comment. In many settings, we would agree with him that household size is associated with socioeconomic status and standard of living. However, in the setting of this outbreak, the socioeconomic status of all residents was uniformly poor, and there was no substantial variation in the living conditions. Although we cannot exclude the possibility that a proportion of secondary cases may have acquired infection from an unidentified common source, we still believe that significant hepatitis E virus personto-person transmission occurred during this large epidemic in northern Uganda. To the Editor-Earlier this year, the Infectious Diseases Society of America (IDSA) published their 2009 International Clinical Practice Guidelines on the diagnosis, prevention, and treatment of catheter-associated urinary tract infection (CA-UTI) in adults [1] . We commend the article's panel of experts for their comprehensive and clinical in-depth review of catheter-associated asymptomatic bacteriuria and symptomatic urinary tract infection. However, we disagree with their specific recommendation that a 5-day regimen of levofloxacin be considered in patients with CA-UTI who are not severely ill. We strongly believe that this recommendation is based on weak supporting data, may have a greater propensity for adverse events, and does not constitute the best use of this fluoroquinolone agent.
The sole specific antimicrobial agent treatment recommendation in the entire document is for using levofloxacin (5 days, no dose cited). Interestingly, the strength assigned to this recommendation is only moderate, and the quality of evidence lacks well-designed clinical trial scrutiny (B-III). It appears that their choice of levofloxacin is based on a single trial which found that levofloxacin (750 mg once daily for 5 days) was both microbiologically and clinically noninferior to ciprofloxacin (400/500 mg twice-daily for 10 days) for the treatment of complicated urinary tract infections and acute pyelonephritis [2] . In a small subset of patients who had a urinary catheter in place, a greater number of levofloxacin-treated (30 [78.9%] of 38) than ciprofloxacin-treated (16 [53.3%] of 30) subjects had their urinary pathogen eradicated (95% confidence interval, 3.6%-47.7%). Nevertheless, clinical success rates (78.9% vs 79.9%) for CA-UTIs were similar for levofloxacin and ciprofloxacin, respectively.
One explanation for the disparity in microbiologic eradication rates in those with catheters in place could be the fact that 23 isolates that were resistant or had intermediate susceptibility to ciprofloxacin remained susceptible to levofloxacin, although details as to the pathogens involved in patients with CA-UTI were not supplied. It is quite possible that more CA-UTIs treated with ciprofloxacin involved gram-positive cocci, organisms against which levofloxacin would likely have an activity advantage over ciprofloxacin. However, regardless of any residual organisms present, once clinical cure is achieved even if asymptomatic bacteriuria persists, a condition the authors and others recommend against documenting, no further antimicrobial intervention is required or recommended. Thus, any real advantage of levofloxacin would be minor or nil (ie, decreasing posttreatment asymptomatic bacteriuria).
By federal drug administration standards, levofloxacin has earned approval as an effective antibiotic for the treatment of complicated and uncomplicated urinary tract infections. However, ultimately this is probably not the optimal use of this agent as recommended in the IDSA CA-UTI practice guidelines (which includes both hospital and long-term care facilities). Its high cost, rising association with Clostridum difficile infection, and implied 750-mg dose (the dose used in the study cited), which may lead to untoward adverse effects in the elderly population, are factors that support our firm suggestion that other antimicrobial agents better suited for the treatment of CA-UTIs should be considered first. There is also the possibility that widespread use of levofloxicin may result in less susceptibility of respiratory pathogens. We feel that ciprofloxacin may be preferred where a fluoroquinolone agent is indicated, based on susceptibility results. Let's generally reserve levofloxacin for the treatment of respiratory tract infections, a role for which it is more appropriately suited.
